Neogen
Maker of food-safety diagnostics, hygiene systems, and animal-care products.
Something off on this page? Send us feedback.
Profile
Sells food and feed testing consumables, culture media, hygiene-monitoring systems, instruments, and analytics software, alongside veterinary, diagnostic, and pest-control products. Food Safety generates most revenue, international customers contribute slightly more than half of sales, and the global genomics-services business is under agreement to be sold.
Develops and manufactures food and animal safety products through two reporting segments. Food Safety supplies mostly single-use tests, culture media, hygiene-monitoring systems, instruments, and analytics software for detecting pathogens, spoilage organisms, allergens, natural toxins, and sanitation failures. Animal Safety sells veterinary instruments and disposables, pharmaceuticals, vaccines, parasiticides, diagnostics, and rodent and insect control products, while its global genomics-services business remains under agreement to be sold to Zoetis.
Generates most revenue from Food Safety and slightly more than half of sales outside the United States. Its recurring workflow pairs proprietary assays and consumables with readers, software, training, and technical support. Operations depend on regulated product approvals and validations, third-party instrument suppliers, and completion of the Petrifilm manufacturing transfer from 3M to Lansing.
Company facts
Key statistics
Year to date +66.6% · Average volume (30d) 2.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Piper Sandler | Upgrade | Neutral | Overweight | ||
| Aug 3, 2026 | Piper Sandler | Reiterate | Neutral | $10 | $13 | |
| Jan 12, 2026 | Piper Sandler | Reiterate | Neutral | $6.50 | $10 | |
| Jan 9, 2026 | Guggenheim | Reiterate | Buy | $12 | ||
| Dec 10, 2025 | CJS Securities | Upgrade | Market Perform | Market Outperform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q4 FY26 | $0.06 | $0.09 | +58.8% | $212.4M | $225.3M | +6.1% | +22.66% |
| Apr 9, 2026Q3 FY26 | $0.04 | $0.09 | +125.0% | $204.5M | $211.2M | +3.3% | −6.18% |
| Jan 8, 2026Q2 FY26 | $0.07 | $0.10 | +42.9% | $207.7M | $224.7M | +8.2% | −0.93% |
| Oct 9, 2025Q1 FY26 | −$0.07 | $0.04 | +154.1% | $203.1M | $209.2M | +3.0% | −10.91% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $221.0M | $225.5M | $209.2M | $224.7M | $211.2M | $225.3M | |
| Gross profit | $87.0M | $92.9M | $95.0M | $106.7M | $99.0M | $107.8M | |
| Operating income | $12.0M | −$13.3M | −$16.1M | −$5.4M | −$3.3M | $3.1M | |
| Net income | −$11.0M | −$612.2M | $36.3M | −$15.9M | −$17.0M | −$11.3M | |
| Diluted EPS | −$0.05 | −$2.82 | $0.17 | −$0.07 | −$0.08 | −$0.05 | |
| Gross margin | 39.4% | 41.2% | 45.4% | 47.5% | 46.9% | 47.8% | |
| Operating margin | 5.4% | -5.9% | -7.7% | -2.4% | -1.6% | 1.4% |
Fiscal years (4-quarter sums)FY22 $527.2M · FY23 $822.4M · FY24 $924.2M · FY25 $894.7M · FY26 $870.4M
Revenue by product · Q4 FY26
Revenue by geography · Q4 FY26
Balance sheet, May 31, 2026Cash & short-term investments $185.5M · Total debt $793.3M · Total assets $3.35B · Shareholders' equity $2.09B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 218.06M · Float 216.50M · 99.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 33.43M | 15.33% | 13F | Aug 7, 2026 |
| Neuberger Berman Group LLC | 16.57M | 7.60% | 13G | Jul 7, 2026 |
| Vanguard Portfolio Management LLC | 13.04M | 5.98% | 13F | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 9.83M | 4.51% | 13F | Aug 11, 2026 |
| Vanguard Capital Management LLC | 9.66M | 4.43% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Mikheal Nassif | director, officer: CEO | +370 | $11.81 |
| Feb 17, 2026 | Mikheal Nassif | director, officer: CEO | +23 | $10.94 |
| Jan 26, 2026 | Mikheal Nassif | director, officer: CEO | +25 | $9.86 |
| Feb 2, 2026 | Mikheal Nassif | director, officer: CEO | +24 | $10.00 |
| Jan 16, 2026 | Mikheal Nassif | director, officer: CEO | +137 | $9.33 |
Peers
- Thermo Fisher Scientific
Broad food-safety workflow rival in PCR, media, and automation
- Bio-Rad Laboratories
Food pathogen PCR and chromogenic-media rival
- IDEXX Laboratories
Livestock, dairy, and poultry diagnostics peer
- Zoetis
Animal-health diagnostics and precision-livestock peer
- BD
Culture-media rival through Difco and BBL formulations
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Neogen | $11.66 | 0.00% | $2.54B | — | 39.8 | 2.9 | −0.1% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| IDEXX Laboratories | $554.99 | +0.09% | $43.78B | 39.3 | 35.6 | 9.6 | +9.7% |
| Zoetis | $77.47 | +0.23% | $32.42B | 12.7 | 12.5 | 3.4 | +0.3% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Median | 39.3 | 23.7 | 4.0 | +0.3% |